Pharmatech Oncology, Inc.

    DENVER, CO, October 21, 2010 /24-7PressRelease/ -- The abstract, to be presented in a poster session by Dr. Jeffrey Vacirca of North Shore Hematology Oncology Associates, includes the additional data published from an ongoing clinical trial of bendamustine and rituximab treatment for patients with relapsed or treatment refractory diffuse large B-cell lymphoma (DLBCL). "This impressive data appears to give us a new alternative in second-line lymphoma treatment," says Dr. Vacirca in a statement. The poster reflects response data on 33 patients, though as of October, 50 patients have been enrolled. This study is scheduled to enroll 60 DLBCL patients, and preliminary data will be presented on treatment safety and response rates observed thus far in the study. The poster will be presented from 6:00pm - 8:00pm on Sunday, December 5th in hall A3/A4, poster number: II-686.

Pharmatech Oncology delivers a unique approach to investigator-sponsored clinical trials (ISTs). Post-New Drug Application (NDA), publication-focused clinical trials are important milestones in the lifecycle of oncology drugs. Successful ISTs produce data to guide secondary Investigational New Drug (IND) decision-making, compendium supported off-label utilization, and advancement of patient care options in the clinic.

"Our multi-center trial ISTs are professionally and centrally administered, with diligent IND, regulatory, enrollment and data management oversight. We deliver high quality data which accurately reflect the performance of agents in community-based oncology practices," emphasizes Anders Malm, Pharmatech Oncology CEO.

About Pharmatech Oncology, Inc.:

Pharmatech Oncology, headquartered in Denver, Colorado, is a Research Management Organization (RMO) dedicated to the highest quality of clinical research. Pharmatech Oncology provides oncology-specific Site Management Organization (SMO) and Contract Research Organization (CRO) services to its network of primarily community-based clinics. While experienced in oncology studies, the company's separate Data Management business entity is also capable of providing services for research projects in other disease indications. Pharmatech Oncology's dedication to rapid enrollment and quality data ensures successful development and utilization of therapeutic products among sponsors, investigators, and patients.

For more information about Pharmatech, please visit www.pharmatechoncology.com.

# # #